Skip to main content

Table 1 Patient characteristics and outcomes.

From: Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma

 

R-CHOP

R-EPOCH

No.

99

51

CD4<100/μL

41%

31%

High aaIPI risk (2-3 factors)

59%

69%

Mean age (years +/- standard deviation)

43.5 (+ 8.3)

42.6 (+8.4)

CR rate

Low risk aaIPI (0-1 factors)

High risk aaIPI (2-3 factors)

76% (60%, 88%)

45% (32%, 58%)

88% (62%, 98%)

60% (42%, 76%)

2 year EFS

Low risk aaIPI (0-1 factors)

High risk IPI (2-3 factors)

57% (36%, 73%)

30% (18%, 43%)

81% (51%, 93%)

59% (41%, 74%)

2 year OS

Low risk aaIPI (0-1 factors)

High risk aaIPI (2-3 factors)

66% (43%, 82%)

36% (23%, 50%)

87% (57%, 97%)

62%, (44%, 76%)